Boston Scientific Corporation (BSX)
BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?
Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are Boston Scientific BSX and Medtronic MDT.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
BSX Raises 2025 Financial Outlook: What's Backing It?
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.
I'm Buying Dividend Aristocrats At Bargain Basement Prices
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-covered dividends. Both carry A/A+ rated balance sheets and have potential for strong total returns with a solid starting yield.
What's Happening With Boston Scientific Stock?
Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins.
Why the Market Dipped But Boston Scientific (BSX) Gained Today
The latest trading day saw Boston Scientific (BSX) settling at $99.74, representing a +1.2% change from its previous close.
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029.
Boston Scientific (BSX) Upgraded to Buy: Here's Why
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
